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https://doi.org/10.1016/j.stemcr.2018.01.037SUMMARYThe LIM-homeodomain transcription factor ISL1 marks multipotent cardiac progenitors that give rise to cardiac muscle, endothelium,
and smoothmuscle cells. ISL1+ progenitors can be derived from human pluripotent stem cells, but the inability to efficiently isolate pure
populations has limited their characterization. Using a genetic selection strategy, we were able to highly enrich ISL1+ cells derived from
humanembryonic stemcells. Comparative quantitative proteomic analysis of enriched ISL1+ cells identifiedALCAM (CD166) as a surface
marker that enabled the isolation of ISL1+ progenitor cells. ALCAM+/ISL1+ progenitors aremultipotent and differentiate into cardiomyo-
cytes, endothelial cells, and smoothmuscle cells. Transplantation of ALCAM+ progenitors enhances tissue recovery, restores cardiac func-
tion, and improves angiogenesis through activation of AKT-MAPK signaling in a ratmodel ofmyocardial infarction, based on cardiacMRI
and histology. Our study establishes an efficient method for scalable purification of human ISL1+ cardiac precursor cells for therapeutic
applications.INTRODUCTION
The LIM-homeodomain transcription factor ISL1 marks an
SHF (second heart field) progenitor population that makes
a substantial contribution to the developing heart after the
initial heart tube formation, giving rise to most cells in the
right ventricle, pacemaker cells, both atria, the outflow
tract, and specific regions of the left ventricle (Buckingham
et al., 2005; Cai et al., 2003; Laugwitz et al., 2005; Liang
et al., 2015; Wu et al., 2008). The ISL1+ progenitors also
differentiate into smoothmuscle cells and endothelial cells
(Bu et al., 2009; Sun et al., 2007).
Despite their significant contribution to the heart, there
is less known about their developmental and regenerative
potential in humans due to limitations in obtaining these
embryonic cells fromprimary samples. Human pluripotent
stem cells (hPSCs) offer a renewable source for obtaining, inSte
This is an open access article under the Cprinciple, unlimited numbers of ISL1+ cardiac progenitors.
However, currently available differentiation protocols yield
highly heterogeneous populations that complicate disease
modeling, drug screening, and regenerative applications.
Several groups have previously shown that a transient
ISL1+ progenitor population emerges at early stages during
cardiac differentiation of hPSCs (Bu et al., 2009). Although
these progenitors are thought to subsequently give rise to
beating cardiomyocytes, their differentiation potency and
molecular characteristics have remained elusive due to
the heterogeneity of the hPSC-derived cultures and lack
of a faithful reporter or surface marker to facilitate purifica-
tion. Moreover, surface markers that have been identified
label either later stage cardiac cells, e.g., SIRPA (Dubois
et al., 2011), or earlier mesodermal committed cells (Druk-
ker et al., 2012). Since ISL1 is a nuclear transcription factor,
it cannot be used directly for purification of ISL1+ cells.m Cell Reports j Vol. 10 j 1–12 j March 13, 2018 j ª 2018 The Authors. 1
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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used to drive expression of a reporter gene that accurately
identifies ISL1-expressing cells.
We then used comparative quantitative proteomics to
search for surface markers that specifically label the ISL1+
cardiac progenitor cells derived from hPSCs. We identified
ALCAM (CD166) as a specific surface marker that can be
used to enrich for these progenitor cells. We further used
this purification strategy to characterize the human ISL1+
cardiac progenitors and demonstrated their potential for
cell therapy in a myocardial infarction model.RESULTS
Purification and Molecular Characterization of ISL1+
Cardiac Progenitors
To facilitate purification and characterization of hPSC-
ISL1+ progenitors, we established a human embryonic
stem cell (hESC) line expressing the hygromycin resistance
gene under control of the ISL1 promoter (Figure S1A). The
modified hESCs (rH5-ISL1-Hygro) express the key pluripo-
tency genes TRA1-60, TRA1-81, OCT4, and NANOG (Fig-
ure S1B), indicating that the genetic modification and
clonal selection did not alter their pluripotent phenotype.
To generate cardiac progenitor cells from the modified
hESCs, we used a modified version of the protocol
described by Laflamme et al. (2007) (Figure 1A), which in-
volves an initial replating step 5 days before treatment
with activin A and bone morphogenetic protein 4
(BMP4). Five days after differentiation, cells significantly
increased the expression of ISL1 gene. Given that ISL1
expression increases progressively between day 5 and day
10 of differentiation (Figures 1B and S1C), we treated the
rH5-ISL1-Hygro cells from day 5 through day 8 with hy-
gromycin to select for the hESC-derived ISL1+ cells (Fig-
ure 1C). The hygromycin selection enriches for ISL1+ cells,
yielding a population of about 90% positive for ISL1 as
assessed by immunofluorescence staining, flow cytometry
(Figure 1D), andwestern blotting experiments (Figure S1D).
The ISL1-enriched cell population also expresses relatively
higher levels of cardiac mesoderm transcription factors
NKX2.5, GATA4, and MEF2C (Figure S1E), the latter of
which is transcriptionally regulated by ISL1 (Dodou et al.,
2004). We maintained differentiated cells for up to
25 days to evaluate the expression pattern of structural pro-
teins and functional characterization of ISL1-enriched
cells. The hygromycin selected cells differentiate into
cardiomyocytes expressing CX43, MYH6, and cardiac
troponin T (Figure S1F), and generate beating cardiomyo-
cytes (Movie S1 and Figure S1F). Multi-electrode array
(MEA) analysis shows that the spontaneous beating cardio-
myocytes increase their beating rate in response to isopren-2 Stem Cell Reports j Vol. 10 j 1–12 j March 13, 2018aline treatment, indicating functional maturation (Figures
S1G and S1H).
A Mass Spectrometry Approach Identifies ALCAM as
ISL1+ Cardiac Progenitor Surface Marker
To further characterize the hESC-derived ISL1+ progenitors
and identify surface markers to facilitate their prospective
isolation, we performed an unbiased global proteomics
analysis. We performed a label-free quantitative shotgun
proteomics assay using a spectral counting approach to
compare the ISL1+-enriched population with nonenriched
age-matched differentiated cells. The hierarchical clus-
tering and list of the differentially expressed proteins is pre-
sented in Figure S2A and Table S1. The key differentially ex-
pressed pathways following ISL1 enrichment revealed by
Qiagen Ingenuity Pathway Analysis were associated with
transcriptional regulators, signaling pathway regulators
(including modulators of WNT and Notch pathways), car-
diovascular development proteins, and cardiovascular dis-
ease-related proteins (Figures S2B–S2E).
Focusing on surface markers that were differentially ex-
pressed in the ISL1+ enriched and unenriched populations,
we identified CD49C and CD276 as potential negative
markers and ALCAM (CD166) as a candidate positive
marker (Figure 1E). Western blotting analysis for selected
differentially expressed surface antigens confirmed the
global proteomics results (Figure S2F). Immunofluores-
cence staining on ISL1+-enriched and unenriched popula-
tions, as well as sorted populations, showed that ALCAM
specifically labels the hESC-derived ISL1+ progenitors (Fig-
ures 2A–2D) while negative sorts for CD49C or CD276 did
not result in a significant enrichment (Figures S2G and
S2H). Immunofluorescence staining confirms co-expres-
sion of ISL1 and MEF2C with ALCAM in hESC-derived car-
diac progenitors (Figure 2E), indicating that ALCAM faith-
fully labels ISL1+ progenitors derived from hESCs.
Time-course gene expression analysis of the hESC-
derived cells by qRT-PCR and flow cytometry reveals that
ALCAM is upregulated at day 8 and maintained in later
stages of differentiation (Figures 2D and 2E). The hESC-
derived ALCAM-sorted cells are multipotent and can be
further differentiated into cardiomyocytes expressing
MYH6, CX43, MLC-2v, c-Actin, SMA+ smooth muscle pre-
cursors, and VE-cadherin+ endothelial cells (Figures 2F, 2G,
and S3A). Persistent expression of ALCAM is also confirmed
by flow cytometry at different time points in differenti-
ating hESCs and human induced PSCs (hiPSCs) (Figures
S3B and S3C).
We then compared the expression pattern of ALCAM
with other previously identified surfacemarkers for various
hPSC-derived cardiac populations. At day 8, when we
expected to see a high percentage of ISL1+ progenitors in
the population, we did not observe a substantial number
ISL1 
0.02 39.4 89.8 
RPMI+ 2%B27 
0 
BMP4 AA Hygro
8 -5 1 5 
+Hygro
rH5-isl1-Hygro hESC Day 8- ISL1+/-
Day 8-ISL1+ 
A
B
D
E Membrane Proteins
SPTAN1
CD49c
CDH1
GPC4
SLC1A5
TSTA3
CD276
PSEN1
NCSTN
SLC38A1
PSMG1
ALCAM
FHL3
JUP
LIN7A
ZYX
−12
−11
−10
−9
−8
ISL1+/-
ISL1+/-
ISL1+/-
ISL1+
ISL1+
ISL1+
C
D
A
PI
IS
L1
hESCs Day 8- no treatment Day 8-Hygro. 
hESCs
Time (days)
IS
L1
 m
RN
A
 re
la
ti
ve
 to
 h
ES
Cs
Day 8-no treatment Day 8-Hygro.
hESC medium
Replating in monolayer
1 3 5 6 7 10 11 15
0
5
10
15
VAT1
**
***
*
* *
Figure 1. Enrichment and Proteomic Characterization of hESC-Derived ISL1+ Progenitors
(A) Schematic representation of the differentiation protocol.
(B) Real-time qRT-PCR for ISL1 expression during cardiac differentiation of rH5-isl1-Hygro. n = 3.
(C) Antibiotic treatment paradigm for enrichment of ISL1+ cells.
(D) Immunofluorescence staining and flow cytometry of hESCs at day 8 of differentiation with or without antibiotic treatment for ISL1.
(E) Membrane proteins that were R1.5-fold differentially expressed (n = 3 independent experiments) between antibiotic-treated cells
versus untreated cells. AA, activin A.
Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar, 75 mm.
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percentage of PDGFRa- and SSEA-1-positive cells were
relatively high and the majority also expressed ALCAM
(Figure S3D).
SIRPA, a recently defined cardiomyocyte precursor
marker (Dubois et al., 2011), is upregulated after the win-
dow of ISL1 expression and is reduced in the differentiated
population, indicating that the two markers label tempo-
rally or developmentally distinct precursor populations
(Figure S3E). Taken together, these data confirm that purifi-
cation of ALCAM+ cells is a reliable approach for obtainingISL1+ multipotent cardiac progenitors from differentiating
hPSCs.
ALCAM-Sorted Cells Exhibit a Gene Expression
Pattern Characteristic of a Proliferative State
We next performed gene expression profiling for ALCAM+,
ALCAM, and the unsorted age-matched differentiated
cells (ALCAM/+), in comparison with undifferentiated
hESCs. We identified 3,366 differentially expressed genes
(DEGs) and clustered them based on their expression
patterns in different cell populations (Figures 3A and 3B;Stem Cell Reports j Vol. 10 j 1–12 j March 13, 2018 3
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Figure 2. ALCAM Labels Multipotent hESC-Derived ISL1+ Progenitors during Cardiac Differentiation
(A and B) ISL1 and ALCAM staining of (A) ISL1+/ and (B) ISL+ populations.
(C) Flow-cytometry analysis for co-expression of ALCAM and ISL1.
(D) ISL1 staining of ALCAM (left panel) and ALCAM+ (right panel) sorted populations.
(E) Immunofluorescent co-staining of ALCAM with ISL1 and MEf2C in differentiated cells.
(F) Time-course qPCR analysis of ALCAM mRNA expression. n = 3–5 independent experiments. *p < 0.05, **p < 0.01.
(G) Time-course flow-cytometry analysis for co-expression of ALCAM and ISL1. The cells were sorted at day 8 for ALCAM for subsequent
characterizations.
(H) Immunolabeling for MYH6, MLC-2v, c-Actin, and CX43 in ALCAM+ sorted populations differentiated toward cardiomyocyte lineage.
(I) Immunolabeling for SMA and VE-cadherin in ALCAM+ sorted populations differentiated toward smooth muscle and endothelial lineages,
respectively.
Scale bars, 100 mm (A and B), 50 mm (D), 10 mm (E, H, and I [right panel]), and 20 mm (I [left panel]).
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Figure 3. Upregulation of Proliferation
Pathways in ALCAM+ Cells
(A) Venn diagram for differentially ex-
pressed genes (DEGs) in ALCAM, ALCAM/+,
and ALCAM+ cells versus hESCs.
(B) Heatmap representing the differential
expression of the genes in the 14 clusters
with distinct expression patterns across the
populations (see Table S2 for the list of
genes in each cluster). The color bar repre-
sents the gradient of log2 fold changes be-
tween the two types of cells indicated in
each column.
(C) Gene ontology and biological processes
enriched in clusters 1 to 7 (C1–C7).
The color bar represents the gradient
of log10(P) where P is the significance
of individual GOBPs being enriched by the
DEGs.
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upregulated in all samples versus hESCs (clusters 1–7, Fig-
ure 3B), to identify cellular processes that are activated
upon differentiation and purification of ALCAM+ progeni-
tors. Enrichment analysis of gene ontology biological pro-
cesses for clusters shows that the genes in cluster 1, which
are upregulated in all three types of cells (ALCAM,
ALCAM/+, and ALCAM+ cells) compared with hESCs,
are mainly involved in the processes related to cardiac
differentiation (cardiac muscle tissue development, heart
development, heart morphogenesis, andmuscle cell differ-
entiation), angiogenesis (blood vessel development and
response to hypoxia), and anti-apoptosis (negative regula-
tion of apoptosis; Figure 3C). The genes that regulate cell
proliferation are significantly enriched in ALCAM+ purified
cells (clusters 5 and 7, Figure 3C), suggesting that they are
in a progenitor state and may have better regenerative po-
tential in cardiac infarction models.
Improvement of Cardiac Function after
Transplantation of ALCAM+ Cells in an In VivoModel
of Myocardial Infarction
To assess the ability of ALCAM+ purified progenitors to
improve cardiac function in vivo, we used a rat left anterior
descending artery (LAD) ligation model of cardiac infarc-
tion. The ALCAM, ALCAM/+ and ALCAM+ cells were in-
jected into the border zone surrounding the infarct area
anteriorly and laterally (53 105) in three places (Figure 4A).
Post-transplantation survival of the cells at the injection
site was confirmed by immunohistochemistry for hu-man-specific marker Hu-Nu. The number of surviving
human cells decreased dramatically after 2 weeks with no
surviving human cells at 28 days (Figure S4A). Tissue regen-
eration capacity of the hESC-derived cells was assessed
2 weeks and 4 weeks after acute myocardial infarction
(AMI) by measuring the thickness of the left ventricular
wall, and size of the fibrotic area using H&E or Masson’s
trichrome staining (Figures S4B and 4B). The ventricular
thickness was increased significantly in animals trans-
planted with ALCAM+ compared with ALCAM,
ALCAM/+, or vehicle control rats (Figures 4B and 4C),
demonstrating the beneficial therapeutic effect of the
enriched cardiac progenitors. The size of the fibrotic area
showed a substantial decrease in all injection groups
compared with the vehicle control group, with the
ALCAM+ group showing the most statistically significant
effect (Figures 4B and 4D).
TUNEL staining of transplanted hearts showed that the
population of apoptotic cells increased up to about 69%
in the control infarcted group but decreased significantly
in all cell transplanted animals, most for the group that
received ALCAM+ precursors (Figures 4E and S4C). The
vehicle control group did not show any improvements
compared with the control AMI group (Figures 4B–4E).
To assess the ability of ALCAM+ cells to improve angio-
genesis, we measured the diameter of blood vessels and
number of capillaries in the infarct area and border area
in all transplanted animals, using a-smooth muscle actin
(a-SMA) and von Willebrand factor (vWF) staining to label
vascular smooth muscle and endothelial cells, respectivelyStem Cell Reports j Vol. 10 j 1–12 j March 13, 2018 5
Figure 4. ALCAM+ Cells Promote Tissue Regeneration and Angiogenesis in AMI Rat Hearts
(A) Paradigm for purification and transplantation of ALCAM+ progenitors.
(B and C) H&E staining and Masson’s trichrome (MT) staining in sham or AMI rat hearts in control, medium only, and ALCAM, ALCAM/+, or
ALCAM+ cell transplanted groups, 4 weeks post transplantation. Insets are high-magnification images of the fibrotic area. Scale bar, 1 mm.
(C) Wall thickness in transplanted hearts measured by H&E staining.
(D) Fibrotic area in transplanted hearts measured by MT staining.
(E) Quantification of TUNEL staining in sham or AMI rat hearts in control, medium only, and ALCAM, ALCAM/+, or ALCAM+ cell trans-
planted groups, 2 and 4 weeks post transplantation.
(legend continued on next page)
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in the diameter of the blood vessels was significantly higher
in ALCAM+ cell transplanted groups compared with
the ALCAM+/, ALCAM, and control groups (Figure 4F).
ALCAM+ transplanted hearts also showed the greatest
increase in number of capillaries in 4 weeks compared
with other groups (Figure 4G). Taken together, these results
show that hESC-derived ALCAM+ cells enhance angiogen-
esis in AMI rats and have a higher regenerative potential
compared with ALCAM+/ and ALCAMcells.
Given the significant impact of transplanted hESC-
derived ALCAM+ cells on overall tissue regeneration in
AMI hearts, we set out to evaluate their effects on func-
tional restoration using magnetic resonance imaging
(MRI). We observed a profound recovery in hearts that
were injected with ALCAM+ cells (Figure S5 and
Movie S2). Ejection fraction in the medium-injected rats
was significantly lower than in the sham-operated rats
(no myocardial infarction) but there was no significant
difference between ALCAM+ cell transplanted hearts and
sham-operated rats (Figure 4H). This finding confirms a
remarkable ability of ALCAM+ cells in almost complete
restoration of ventricular function back to normal (n = 3).
In addition, preliminary studies showed a trend toward
improved wall thickness (Figure 4I) and infarct size
(Figure 4J) in ALCAM+ transplanted hearts versus the
medium-treated hearts as measured by cardiac MRI imag-
ing. These results demonstrate the potential of ALCAM+
hESC-derived cardiac progenitors for cell therapy in
myocardial infarction.
ALCAM+ Purified Progenitors Increase Angiogenesis
through Activation of MAPK/ERK, AKT, and JNK
Pathways
It is known that angiogenesis can be stimulated through
activation of MAPK and AKT pathways (Zhu et al., 2002).
To understand the mechanism through which the trans-
planted ALCAM+ cells improve angiogenesis, we moni-
tored control and transplanted hearts 4 weeks after injec-
tion, and measured changes in the levels of AKT, pAKT,
ERK1/2, pERK1/2, SAPK/JNK, and pSAPK/JNK (Figure 5A).
The levels of AKT, ERK, and SAPK/JNK were similarly
increased in all cell treatment groups. However, the phos-(F) Quantification of vessel diameter by SMA staining in infarct area (
control, medium only, and ALCAM, ALCAM/+, or ALCAM+ cell transp
(G) Quantification of capillary numbers by vWF staining in infarct area
control, medium only, and ALCAM, ALCAM/+, or ALCAM+ cell transp
(H) In vivo MRI quantification of ejection fraction in sham, vehicle,
(I) Representative MRI images showing regions of interest in medium (
transplantation. Scale bars, 0.5 mm.
(J) Infarct size measurements in sham, control, and ALCAM+ cell inje
*p < 0.05, **p < 0.01, ***p < 0.001.phorylated active forms of these signaling molecules,
pAKT (Figure 5B), pERK1/2 (Figure 5C), and pSAPK/JNK
(Figure 5D), were increased most significantly in the
ALCAM+ transplanted group, indicating higher activity of
these angiogenic factors in ALCAM+ cells. Taken together,
these data confirm the superior regenerative potential of
ALCAM+-enriched progenitor cells compared with unen-
riched populations.DISCUSSION
hPSCs offer a renewable source of cardiac lineages for basic
and translational investigations. However, currently avail-
able differentiation protocols yield heterogeneous popula-
tions that limit their utilization in regenerative medicine.
There have been previous attempts to establish surface
marker-based methods for purification of cardiomyocyte
precursors at various stages of in vitro differentiation (Arde-
hali et al., 2013; Dubois et al., 2011). SIRPA, KDR/PDGFRa,
and SSEA4 are among the most common markers that
have been used for prospective isolation of cardiac lineages
on the basis of co-expression with cardiomyocyte specific
markers. Our study is focused on a distinct progenitor stage
that is labeled by the transcription factor ISL1. During devel-
opment, ISL1 marks undifferentiated cardiac progenitors
that will contribute to the second wave of cardiogenesis
(Liang et al., 2015). These precursors give rise to cardiac
smooth muscle, endothelium, pacemakers, and a substan-
tial population of cardiomyocytes. We used a genetic selec-
tion approach to obtain enriched ISL1+ progenitors from
cardiac differentiation cultures derived fromhESCs and sub-
jected them to quantitative proteomic characterization.
Pathway analysis suggested that proteins involved in WNT
and Notch signaling pathways regulate ISL+ cardiac progen-
itors, confirming previous findings in murine models
(Kwon et al., 2009). In addition, several proteins related to
cardiac disease and arrhythmias were among the differen-
tially expressed proteins identified, providing useful leads
for further studies in disease modeling. Analysis of mem-
brane proteins enriched in the purified ISL1+ population
identified ALCAM (CD166) as a surface marker that can be
utilized for prospective isolation of these progenitors fromleft panel) or border area (right panel) in sham or AMI rat hearts in
lanted groups, 2 and 4 weeks post transplantation.
(left panel) or border area (right panel) in sham or AMI rat hearts in
lanted groups, 2 and 4 weeks post transplantation.
and ALCAM+ cell injected AMI hearts.
upper graph) and ALCAM+ AMI (lower graph) rat hearts 4 weeks after
cted AMI hearts from in vivo MRI. n = 3 independent experiments.
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Figure 5. ALCAM+ Cells Promote Angiogenesis in AMI Rat Hearts through AKT, MAPK, and JNK Pathways
(A–C) Immunohistochemistry for Akt, pAkt (A), ERK1/2, pERK1/2 (B), and SAPK/JNK, pSAPK/JNK (C), in AMI rat hearts in control, medium
only, and ALCAM, ALCAM/+, or ALCAM+ cell transplanted groups, 4 weeks post transplantation. n = 3 independent experiments. The black
arrows point to positive signals. Scale bars, 100 mm.
(D) Quantification of distribution of Akt, pAkt, ERK1/2, pERK1/2, SAPK/JNK, and pSAPK/JNK. *p < 0.05, **p < 0.01, ***p < 0.001.
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expression at the early stages of differentiation; however,
unlike ISL1, it persists through differentiation into mature
cardiomyocytes. We also observed that ALCAM has a
distinct expressionpattern comparedwith other cardiac sur-
face markers such as SIRPA, which is considered to label
more mature cardiomyocytes. Therefore, ALCAM offers a
purification strategy for isolation of an earlier and poten-
tially more plastic progenitor population.8 Stem Cell Reports j Vol. 10 j 1–12 j March 13, 2018ALCAM has been previously shown to mark mature and
functional cardiomyocytes and also to mark murine sino-
atrial cells, all of which are derivatives of ISL1+ cardiac pro-
genitors during development (Liang et al., 2015; Lin et al.,
2012; Scavone et al., 2013). An interesting finding of our
present study is that ALCAM+ cells that are isolated at early
stages of differentiation can generate multiple cell types of
interest, including functional cardiomyocytes, endothelial
cells, and smoothmuscle cells. In a recent study, Fernandes
Please cite this article in press as: Ghazizadeh et al., Prospective Isolation of ISL1+ Cardiac Progenitors from Human ESCs for Myocardial
Infarction Therapy, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.01.037et al. (2015) showed that transplantation of a differentiated
population that contains endothelial precursors in addi-
tion to cardiomyocytes better improves cardiac function
compared with cardiomyocyte committed precursors.
Using a rat model of cardiac infarction, we demon-
strated that transplanted ALCAM+ hESC-derived progeni-
tors show a remarkable capacity to promote histological
and functional restoration compared with unsorted and
ALCAM cells, suggesting that the enrichment step facili-
tates optimal tissue regeneration after cell-based treat-
ment. It is possible that by using ALCAM+ cardiac progen-
itors for transplantation, we could benefit from their
potential in differentiating toward smooth muscle and
endothelial cells as well as their higher proliferation capac-
ity, as shown by microarray studies. However, the mecha-
nisms by which ALCAM+ cells promote regeneration
remains unclear. It is possible that the effect is mediated
by secretion of paracrine factors to stimulate endogenous
repair or the ability of transplanted cells to promote
the formation of functional blood vessels and thereby
enhance tissue recovery. It would be interesting to
compare the regenerative impact of ALCAM+ cell trans-
plantation with injection of angiogenic factors such as
vascular endothelial growth factor to define the role of
angiogenesis in the overall repair process.
Furthermore, we showed that the increase in angiogen-
esis is associated in ALCAM+ grafts with elevated levels
of pAKT, a well-known modulator of angiogenesis. One
advantage of the current study over previous reports is
the application of cardiac MRI for live assessment of heart
function after transplantation. We confirmed functional
restoration of the infarcted hearts after transplantation
of ALCAM+ progenitors. The MRI approach enables a
noninvasive, accurate, and direct assessment of heart
function in infarcted hearts by measuring infarction area
and ejection fraction. However, one of the limitations of
the current study was the limited number of animals
analyzed by cardiac MRI. To provide a more comprehen-
sive understanding of heart function after transplanta-
tion, future studies will involve larger animal cohorts.
Moreover, implementation of approaches that increase
the survival of progenitors after transplantation such
as pretreatment with pro-survival factors and/or encapsu-
lation methods could increase the survival following
transplantation.
Taken together, our data provide an efficient strategy
for large-scale selection of highly enriched human ISL1+
cardiac progenitors. These cells can be employed for
translational applications in cardiac repair, as well as in
developmental and disease-related studies. Our approach
establishes a template for systematic characterization of
various cardiac progenitor populations and dissection of
their developmental and regenerative potential.EXPERIMENTAL PROCEDURES
Culture of Undifferentiated Human ESCs
Adherent colonies of hESC line H9 (WA-09), hESC line Royan
H5 and derivatives (rH5-ISL1-Hygro), as well as two independent
hiPSC lines (hiPSC1, bj-iPSC1) were maintained on mouse
embryonic fibroblasts in knockout serum replacement (KOSR;
Invitrogen, #10828-028) containing hESC medium as described
previously (Fonoudi et al., 2013).
Generation of ISL1-Hygro hESCs
The hygromycin resistance gene was PCR amplified and subcl-
oned into pBlue-TOPO vector (Life Technologies, #K4831-01).
To generate the ISL1-based selection construct, we PCR amplified
a 4.1-kb fragment of human ISL1 promoter from human genomic
DNA using the Expand Long Template PCR System (Roche,
#11681834001). The amplified fragment was cloned in the
multiple cloning site of the pBlue-TOPO vector containing
the hygromycin resistance fragment using AflII and BglII diges-
tion. The ISL1-Hygro construct was sequenced for validation.
To generate the ISL1-Hygro hESC line, we plated and transfected
single cells with the construct using Fugene 6 (Promega, #E2693)
according to the manufacturer’s instructions. The cells were
cultured in G418 (Sigma, #A1720)-containing medium for
7 days and resistant colonies were selected for expansion and
follow-up validations.
Cardiac Induction
hESCs were plated on Matrigel-coated dishes (105 cells/cm2) in
hESC medium containing 100 ng/mL fibroblast growth factor 2
(R&D Systems, #233-FB-001MG/CF). Differentiation was initiated
in RPMI-1640 medium (Gibco, #51800-035) supplemented with
2%B27withoutvitaminA (Gibco,#12587-010), 2mML-glutamine
(Gibco, #25030-024), 1 mM nonessential amino acids (Gibco,
#11140-035), 13 penicillin/streptomycin (Gibco, #15070-063),
and 0.1 mM b-mercaptoethanol (Sigma-Aldrich, #M7522), and
containing activin A (100 ng/mL, R&D, #338-AC-050) for 1 day
and BMP4 (10 ng/mL, R&D, #314-BP-010) from days 2–5.
Enrichment of ISL1+ cells was accomplished by treatment with
hygromycin (10 mM) from day 5 through day 8. The differentiated
cells (ISL1+ and ISL+/) were harvested for protein purification on
day 8.
Multi-electrode Array
Extracellular recordingswere performedwith anMEAdata-acquisi-
tion system (Multi Channel Systems, Reutlingen, Germany). The
MEA plates contained a matrix of 60 titanium nitride electrodes
(30 mm in diameter) with an inter-electrode distance of 200 mm.
The signal recorded with one of the extracellular electrodes reflects
local changes of the membrane potential. The MEA plates were
sterilized and coated with polyornithine/laminin/fibronectin.
Standard measurements were acquired at 5 kHz (at 37C). Record-
ings were performed 48 hr after plating, for 100 s at baseline, and at
5 min after 100 nM isoprenaline. The parameters including filed
potential duration (ms), peak amplitude (mV) inter-spike interval
duration (ms), and beating rate (beats/min) were analyzed using
AxoScope software (Molecular Devices) and CardioMDA.Stem Cell Reports j Vol. 10 j 1–12 j March 13, 2018 9
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Immunofluorescence Analysis
For immunofluorescence, cellswerewashed three timeswithPBSso-
lution and fixed in 4% paraformaldehyde (Sigma-Aldrich, #P6148)
for 20 min, then blocked and permeabilized using 0.3% (v/v) PBS/
Triton X-100 and 5% heat-inactivated horse serum for 20 min at
room temperature. The cells were then incubated overnight at 4C
with the appropriate primary antibodies and stained with fluoro-
phore-conjugated secondary antibody at room temperature for
1 hr before imaging. For fluorescence-activated cell sorting analysis,
cellswere dissociated usingAccutase (InnovativeCell Technologies,
#AT104) treatment for 5 min and fixed and permeabilized using
BD Cytofix/Cytoperm solution (Becton Dickinson, #554722) for
30min at 4C. After washing twice with PBS, the final pellet was re-
suspended in 200 mL of BD Perm/Wash buffer (Becton Dickinson,
#554723) plus 5% horse serum and incubated for 30 min on ice.
The cells were then stained with primary (overnight at 4C) and
secondary (1 hr at 4C) antibodies and analyzed using Flowjo 8.7
software (Tree Star). A list of primary antibodies and their working
dilutions is provided in Supplemental Experimental Procedures.
Gene Expression Analysis
For RNA sequencing, total RNA was extracted using the RNeasy
Mini Kit (Qiagen, #74104) according to the manufacturer’s proto-
col. For qRT-PCR assay, 2 mg of total RNAwas reverse transcribed to
cDNA using RevertAid First Strand cDNA Synthesis Kit (Fermentas,
#K1621). qRT-PCR reactions used SYBRPremix Ex Taq II (Takara
Bio, #RR081Q). Each data point represents three independent
biological replicates.
Protein Separation
Extracted proteins from each sample (150 mg) were fractionated on
a 10% Bis-Tris polyacrylamide gels. After staining and washing,
each lane was cut into 16 equal pieces from top to bottom, with
each piece further sliced into smaller pieces and transferred to
a 96-well plate. Gel pieces were briefly washed with 100 mM
NH4HCO3 and then three times with acetonitrile (can) (50%)/
100 mM NH4HCO3 (50%), before dehydration with 100% ACN
(5 min). Samples were then air dried, reduced with 10 mM DTT/
50 mM NH4HCO3 for 1 hr at 37
C, and alkylated with 50 mM
iodoacetamide/50 mM NH4HCO3 for 1 hr at room temperature
in darkness. Samples were then digested with 20 mL of trypsin
(12.5 ng/mL in 50 mM NH4HCO3) for 30 min on ice and at 37
C
overnight. Resultant peptides were extracted twice with 50 mL of
50% ACN/2% formic acid, dried, vacuum centrifuged, and recon-
stituted to 10 mL with 2% formic acid.
Nanoflow Liquid Chromatography-Tandem Mass
Spectrometry
Extracted SDS-PAGE gel tryptic digests were analyzed by nanoflow
liquid chromatography-tandem mass spectrometry using an LTQ-
XL linear ion-trap mass spectrometer (Thermo, San Jose, CA).
Reversed-phase chromatography columns were packed to approx-
imately 7 cm length in 100-mm internal diameter tubing using
100 A˚, 5 mM Zorbax C18 resin (Agilent Technologies, Santa Clara,
CA) in a fused silica capillary with an integrated electrospray tip.
An electrospray voltage of 1.8 kVwas supplied via a liquid junction10 Stem Cell Reports j Vol. 10 j 1–12 j March 13, 2018upstream of the C18 column. Injection of samples onto the C18
columns was performed using a Surveyor autosampler (Thermo).
Each sample loaded onto the C18 column was subjected to an
initial wash with buffer A (5% [v/v] ACN, 0.1% [v/v] formic acid)
for 10 min at 1 mL/min. Peptides were subsequently eluted with
0%–50% buffer B (95% [v/v] ACN, 0.1% [v/v] formic acid) over
58 min at 500 nL/min, followed by 50%–95% buffer B over
5 min at 500 nL/min, with the eluent directed into the nanospray
ionization source of the mass spectrometer and scanned over the
range of 400–1,500 atomicmass units. Tandemmass spectrometry
of the top six most intense precursor ions at 35% normalization
collision energy was performed using Xcalibur software (version
2.06; Thermo). Normalized spectral abundance factor values
were calculated for each reproducibly identified protein as previ-
ously described (Zybailov et al., 2006). Proteins that were present
in all three biological replicates with a summed spectral count of
at least 6 were considered to be reproducibly identified and were
included in the final dataset. Specific details on statistical analysis
are provided in Supplemental Experimental Procedures.
Western Blot Analysis
Proteins were separated by 12% SDS-PAGE electrophoresis at 100 V
for 2 hr using aMini-PROTEAN 3 electrophoresis cell (Bio-Rad) and
transferred to a PVDF membrane by wet blotting (Bio-Rad). Mem-
branes were blocked for 1 hr with 5% BSA and incubated for
1.5 hr at room temperature with appropriate primary antibodies.
At the end of the incubation period, membranes were rinsed and
incubated with anti-rabbit secondary antibody (Sigma-Aldrich,
#A0545) conjugatedwith horseradish peroxidase. Blotswere visual-
izedwith ECL substrate (GE)with a densitometer (GS-800, Bio-Rad).
Cell Transplantation in Myocardial Infarction Model
Thirtymale Sprague-Dawley ratsweighing 290–330 g (8–9weeks of
age) were used in this study. The rats were intubated and ventilated
with a volume-cycled small-animal ventilator (Harvard Appa-
ratus). Anesthesia was maintained during the operation with aspi-
ration of 5% isoflurane. The chest was opened and once the LAD
was identified, it was ligated by 6-0 polypropylene. After ligation,
ALCAM+, ALCAM, or ALCAM+/ cells were injected into the
border zone surrounding the infarct area anteriorly and laterally
(5 3 105) in three places with a 10-mL Hamilton syringe. The mus-
cle layer of thorax and skinwere closed and the rats were allowed to
recover. A sham-operated group of animals underwent the same
experimental procedure of chest surgery without LAD ligation
and cell transplantation. To prevent graft rejection, we treated
rats that received cell transplantation with cyclosporine A
(10 mg/kg/day). All experimental procedures were performed in
accordance with the Institutional Guidelines for Animal Experi-
ments (AAALAC of Gachon University LCDI) and IRB approval
(# LCDI-2014-0020). Specific details on evaluation of infarct size,
TUNEL assay, immunostaining, immunohistoenzymic 3,30-diami-
nobenzidine staining, and cardiac MRI are provided in Supple-
mental Experimental Procedures.
Microarray Analysis
mRNA expression profiles of H9 hESCs, ALCAM, ALCAM/+, and
ALCAM+ cells were generated using the Agilent-039494 Human
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21,755 annotated genes (Agilent). Under each condition gene
expression profiling was performed, according to the manufac-
turer’s instructions, on two biological replicates obtained from in-
dependent cell cultures. Total RNAwas extracted, and the integrity
of the total RNA was analyzed using an Agilent 2100 Bioanalyzer.
RNA integrity numbers for all the samples were larger than 8.
In vitro transcription was then performed to generate cRNA, which
was hybridized onto each array. The array was scanned using a
SureScan Microarray Scanner (Agilent).
The log2 intensities of the probes from the arrays were normal-
ized using quantile normalization methods (Bolstad et al., 2003).
To identify DEGs, we performed an integrative statistical hypothe-
sis test as previously described (Chae et al., 2013). In brief, for each
gene we calculated a T-statistic value using Student’s t test and also
a log2-median-ratio in each comparison.We then estimated empir-
ical distributions of T statistics and log2-median-ratio for the
null hypothesis (i.e., the genes are not differentially expressed)
by performing all possible combinations of random permutations
of samples. Using the estimated empirical distributions, we
computed adjusted p values for the t test and log2-median-ratio
test for each gene and then combined these p values using
Stouffer’s method (Hwang et al., 2005). Finally, we identified
DEGs as the genes with combined p values of%0.05 and absolute
log2-median-ratios of R1 (2-fold change). The gene expression
dataset was deposited in the GEO database under the accession
number GEO: GSE109339.Densitometry and Statistical Analysis
The densitometric intensity of each immunoreactive band was
determined using Image-Pro gel digitizing software. All data shown
in this study represent results from at least three independent
experiments. Statistical analyses were performed using the Stu-
dent’s t test, and a p value of less than 0.05 was considered signif-
icant (*p < 0.1, **p < 0.01, ***p < 0.001 in figures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, three tables, and two movies and can be
found with this article online at https://doi.org/10.1016/j.stemcr.
2018.01.037.
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